Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | Future considerations for MRD in AML

Peter Valk • 29 Sep 2022
SOHO 2022
Acute Myeloid Leukemia Leukemia

In this video, Peter Valk, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, briefly discusses the growing use of measurable residual disease (MRD) in acute myeloid leukemia (AML), and further highlights future considerations for next-generation sequencing (NGS)-based techniques and biomarkers of interest. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Peter Valk

2:20
Distinguishing between de novo AML and secondary AML using mutational signatures
Peter Valk • 29 Sep 2022
3:22
Is TP53-mutated high-risk MDS the same disease as TP53-mutated AML?
Peter Valk • 29 Sep 2022
1:49
The prognostic value of FLT3-ITD residual disease in AML
Peter Valk • 29 Sep 2022
2:44
Ongoing and future AML research at the Valk Lab
Peter Valk • 1 Apr 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals